For people with ovarian cancer, advances in targeted treatments are opening the door to new ways of treating the disease. One approach gaining attention is antibody-drug conjugates (ADCs), which are designed to find cancer cells and deliver treatment directly to them. By combining a targeted antibody with a powerful chemotherapy drug, ADCs aim to attack cancer while potentially reducing exposure to healthy cells.
In our recent Ask the Expert webinar covering the latest ovarian cancer research presented at ASCO 2026, gynecologic oncologist Dr. Kari Hacker explained how ADCs like mirvetuximab soravtansine work, why these therapies are an important area of research in ovarian cancer, and what patients should know about their potential benefits and side effects.
Looking for more information? Access trusted educational resources designed to help you navigate ovarian cancer treatment.
